Emergence of Ceftazidime–Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11 Klebsiella pneumoniae During Antibiotics Treatment

References

• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw282
   PubMed Web of Science ®Google Scholar
• Han X, Shi Q, Mao Y, et al. Emergence of ceftazidime/avibactam and tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae due to in-host microevolution. Front Cell Infect Microbiol. 2021;11:757470. doi:10.3389/fcimb.2021.757470
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770. doi:10.1002/phar.1622
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw636
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):1. doi:10.1128/AAC.02101-17
   Web of Science ®Google Scholar
• Chen YT, Chang HY, Lai YC, Pan CC, Tsai SF, Peng HL. Sequencing and analysis of the large virulence plasmid pLVPK of Klebsiella pneumoniae CG43. Gene. 2004;337:189–198. doi:10.1016/j.gene.2004.05.008
   PubMed Web of Science ®Google Scholar
• Walker KA, Treat LP, Sepulveda VE, Miller VL. The small protein RmpD drives hypermucoviscosity in Klebsiella pneumoniae. mBio. 2020;11(5). doi:10.1128/mBio.01750-20
   Web of Science ®Google Scholar
• Nassif X, Fournier JM, Arondel J, Sansonetti PJ. Mucoid phenotype of Klebsiella pneumoniae is a plasmid-encoded virulence factor. Infect Immun. 1989;57(2):546–552. doi:10.1128/iai.57.2.546-552.1989
   PubMed Web of Science ®Google Scholar
• Walker KA, Miner TA, Palacios M, et al. A Klebsiella pneumoniae regulatory mutant has reduced capsule expression but retains hypermucoviscosity. mBio. 2019;10(2). doi:10.1128/mBio.00089-19
   Web of Science ®Google Scholar
• Ye M, Liao C, Shang M, et al. Reduced virulence and enhanced host adaption during antibiotics therapy: a story of a within-host carbapenem-resistant Klebsiella pneumoniae sequence type 11 evolution in a patient with a serious scrotal abscess”. mSystems. 2022;7:e0054522. doi:10.1128/msystems.00545-22
   Web of Science ®Google Scholar
• Xie M, Yang X, Xu Q, et al. Clinical evolution of ST11 carbapenem resistant and hypervirulent Klebsiella pneumoniae. Commun Biol. 2021;4(1):650. doi:10.1038/s42003-021-02148-4
   PubMed Web of Science ®Google Scholar
• Findlay J, Poirel L, Juhas M, Nordmann P. KPC-mediated resistance to ceftazidime-avibactam and collateral effects in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2021;65(9):e0089021. doi:10.1128/AAC.00890-21
   PubMed Web of Science ®Google Scholar
• Li D, Liao W, Huang HH, et al. Emergence of hypervirulent ceftazidime/avibactam-resistant Klebsiella pneumoniae isolates in a Chinese tertiary hospital. Infect Drug Resist. 2020;13:2673–2680. doi:10.2147/IDR.S257477
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin Y, Zhang X, et al. Combining colistin with furanone C-30 rescues colistin resistance of gram-negative bacteria in vitro and in vivo. Microbiol Spectr. 2021;9(3):e0123121. doi:10.1128/Spectrum.01231-21
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: CLSI Supplement M100. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters; 2021. Available from: http://www.eucast.org. Accessed November 23, 2022.
   Google Scholar
• Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199(5):697–705. doi:10.1084/jem.20030857
   PubMed Web of Science ®Google Scholar
• Palacios M, Miner TA, Frederick DR, et al. Identification of two regulators of virulence that are conserved in Klebsiella pneumoniae classical and hypervirulent strains. mBio. 2018;9(4). doi:10.1128/mBio.01443-18
   Web of Science ®Google Scholar
• Palacios M, Broberg CA, Walker KA, Miller VL. A serendipitous mutation reveals the severe virulence defect of a Klebsiella pneumoniae fepB mutant. mSphere. 2017;2(4). doi:10.1128/mSphere.00341-17
   Web of Science ®Google Scholar
• Chen L, Yu K, Chen L, et al. Synergistic activity and biofilm formation effect of colistin combined with PFK-158 against colistin-resistant gram-negative bacteria. Infect Drug Resist. 2021;14:2143–2154. doi:10.2147/IDR.S309912
   Web of Science ®Google Scholar
• Tsai CJ, Loh JM, Proft T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence. 2016;7(3):214–229. doi:10.1080/21505594.2015.1135289
   PubMed Web of Science ®Google Scholar
• Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27(5):722–736. doi:10.1101/gr.215087.116
   PubMed Web of Science ®Google Scholar
• Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006;34:D32–6. doi:10.1093/nar/gkj014
   PubMed Web of Science ®Google Scholar
• Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–2069. doi:10.1093/bioinformatics/btu153
   PubMed Web of Science ®Google Scholar
• Bortolaia V, Kaas RS, Ruppe E, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75(12):3491–3500. doi:10.1093/jac/dkaa345
   PubMed Web of Science ®Google Scholar
• Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex. Nat Commun. 2021;12(1):4188. doi:10.1038/s41467-021-24448-3
   PubMed Web of Science ®Google Scholar
• Zarate JO, Santos Lucero R, Padorno LO, Espiniella F, Apud A. Variantes para la demostracion histologica del Campylobacter pilorico con microscopia optica. [Variants for the histological demonstration of pyloric Campylobacter with optical microscopy]. Acta Gastroenterol Latinoam. 1987;16(4):233–240.
   Google Scholar
• Sun L, Li H, Wang Q, Liu Y, Cao B. Increased gene expression and copy number of mutated blaKPC lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae. BMC Microbiol. 2021;21(1):230. doi:10.1186/s12866-021-02293-0
   Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2017;61(5):1. doi:10.1128/AAC.02534-16
   Web of Science ®Google Scholar
• Shi Q, Yin D, Han R, et al. Emergence and recovery of ceftazidime-avibactam resistance in blaKPC-33-harboring Klebsiella pneumoniae sequence type 11 isolates in China. Clin Infect Dis. 2020;71(Suppl4):S436–S439. doi:10.1093/cid/ciaa1521
   Web of Science ®Google Scholar
• Wang C, Zhao J, Liu Z, et al. In vivo selection of imipenem resistance among ceftazidime-avibactam-resistant, imipenem-susceptible Klebsiella pneumoniae isolate with KPC-33 carbapenemase. Front Microbiol. 2021;12:727946. doi:10.3389/fmicb.2021.727946
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microbiol Infect. 2020;26(1):124e1–124 e4. doi:10.1016/j.cmi.2019.08.020
   Web of Science ®Google Scholar
• Chen L, Kreiswirth BN. Convergence of carbapenem-resistance and hypervirulence in Klebsiella pneumoniae. Lancet Infect Dis. 2018;18(1):2–3. doi:10.1016/S1473-3099(17)30517-0
   PubMed Web of Science ®Google Scholar
• Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015;83(8):3325–3333. doi:10.1128/IAI.00430-15
   PubMed Web of Science ®Google Scholar
• Cheng HY, Chen YS, Wu CY, Chang HY, Lai YC, Peng HL. RmpA regulation of capsular polysaccharide biosynthesis in Klebsiella pneumoniae CG43. J Bacteriol. 2010;192(12):3144–3158. doi:10.1128/JB.00031-10
   PubMed Web of Science ®Google Scholar
• Yu WL, Lee MF, Tang HJ, Chang MC, Chuang YC. Low prevalence of rmpA and high tendency of rmpA mutation correspond to low virulence of extended spectrum beta-lactamase-producing Klebsiella pneumoniae isolates. Virulence. 2015;6(2):162–172. doi:10.1080/21505594.2015.1016703
   PubMed Web of Science ®Google Scholar
• Choi MJ, Ko KS. Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains. Antimicrob Agents Chemother. 2015;59(11):6763–6773. doi:10.1128/AAC.00952-15
   PubMed Web of Science ®Google Scholar
• Park S, Lee H, Shin D, Ko KS. Change of hypermucoviscosity in the development of tigecycline resistance in hypervirulent Klebsiella pneumoniae sequence type 23 strains. Microorganisms. 2020;8(10):1. doi:10.3390/microorganisms8101562
   Web of Science ®Google Scholar